Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fertnstert.2012.06.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Commentary on 'Factors associated with patient activation in people with heart failure based on the individual and family self-management theory: a cross-sectional study'.
Eur J Cardiovasc Nurs
January 2025
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Viale Montpellier 1, 00133 Rome, Italy.
Commentary. Leadership development in health and medicine: Insights, innovations, and applications.
Health Serv Manage Res
February 2025
Department of Biomedical Science, Research Center in Health Administration, University of Milan, Milan, Italy.
Reflections on the 2024 Final Rule on Public Health Service Policies on Research Misconduct.
Account Res
January 2025
Department of Philosophy, Georgetown University, Washington, USA.
Background: The Office of Research Integrity (ORI) of the U.S. Department of Health and Human Services (HHS) recently issued the 2024 Final Rule on Public Health Service Policies on Research Misconduct (42 CFR 93), the first major revision of the regulation in nearly twenty years.
View Article and Find Full Text PDFNonnegligible cascading impacts of global urban expansion on net primary productivity.
PNAS Nexus
January 2025
Key Laboratory of Geographic Information Science (Ministry of Education), School of Geographic Sciences, East China Normal University, Shanghai 200241, China.
Accelerated global urban expansion not only directly occupies surrounding ecosystems, but also induces cascading losses of natural vegetation elsewhere through cropland displacement. Yet, how such effects alter the net primary productivity (NPP) worldwide remains unclear. Here, we quantified the direct and cascading impacts of global urban expansion on terrestrial NPP from 1992 to 2020 and projected the impacts under the shared socioeconomic pathways framework by 2100.
View Article and Find Full Text PDFA review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole.
Curr Med Res Opin
January 2025
Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a long-acting injectable antipsychotic that was approved for use in Europe in March 2024, for the maintenance treatment of schizophrenia in adult patients stabilized with aripiprazole; it is administered via gluteal intramuscular injection once every two months. This review examines population pharmacokinetic model-based simulations relevant to the use of Ari 2MRTU in Europe, accompanied by expert commentary that contextualizes the simulations and highlights the potential implications of the availability of Ari 2MRTU for patients, caregivers, and clinicians. Various simulations conducted across 8 weeks (representing the first dosing interval), or 32 weeks (representing maintenance dosing) demonstrated an aripiprazole exposure profile for Ari 2MRTU that was similar to aripiprazole once-monthly (AOM), but with an extended dosing interval.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!